Literature DB >> 469382

The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.

S N Gitel, S Wessler.   

Abstract

An animal model for the production of stasis thrombi was employed to obtain the data reported in this study. Rabbits treated with warfarin (1.5 mg/kg/day) exhibited a maximal increase in prothrombin time and decreases in factor VII, factor X, and prothrombin within 48 hr with no additional changes occurring after 10 days of drug administration. In contrast, Xa inhibitory activity was unchanged after 48 hr of warfarin treatment but was significantly increased by the tenth day. When thrombosis was induced by infusions of 60 micrograms of tissue thromboplastin, the warfarin regimen produced an antithrombotic effect by the sixth hour, which increased to significance by day 2 and was further significantly increased by day 10. These three stages correspond to the initial depletion of the vitamin K-dependent clotting factors, the maximal depletion of these proteins, and the maximal increase in Xa inhibitory activity, respectively. Thus these experiments separate the antithrombotic potential of warfarin into two components: an early effect related to the decrease in factor VII and a delayed augmentation of Xa inhibitory acticity. Intravenous heparin alone (5 U/kg) did not protect against infusions of 60 micrograms of tissue thromboplastin but did provide an antithrombotic effect against 45 micrograms of the same infusate. Higher doses of heparin, however, did protect against infusion of 60 micrograms of tissue thromboplastin. After 48 hr of warfarin treatment, 5 U/kg heparin increased protection against 60 micrograms of tissue thromboplastin to a degree equivalent to that provided after 10 days of warfarin therapy alone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 469382

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

1.  Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event--first year and long-term comparative mortality.

Authors:  J J Sayen; R B Singer; G Peirce; O Horwitz
Journal:  Trans Am Clin Climatol Assoc       Date:  1983

2.  A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.

Authors:  Xin Huang; Wei-Qun Ding; Joshua L Vaught; Roman F Wolf; James H Morrissey; Roger G Harrison; Stuart E Lind
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

3.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 4.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.